UCL Technology Fund

Gaussion develops a novel solution that utilizes magneto-electrochemistry to enable rapid charging by steering ions within existing battery cells. The magnetic field also lowers cell degradation, extending battery life.

Intrinsic Semiconductor Technologies is established to developed silicon-oxide based RRAM technologies. Intrinsic's technology is fully air stable and inherently CMOS compatible. Intrinsic's core technology can be configured as non-volatile memory, multilevel memory, hardware acceleration for Machine Learning, and neuromorphic devices.

Bramble Energy is an innovator energy technology company that designs and manufactures high-performance, low-cost, and fuel cell stack. The company ability to leverage the global high-volume PCB industry means that they are the first fuel cell company with the manufacturing capacity to supply gigawatts of fuel cell hardware, something the battery industry has spent many years and £B’s to achieve. Bramble Energy specifically uses a printed circuit board (PCB) technology to form the structural parts of the fuel cell. It also provides products including modular PCBFC stacks, H20:20W PCBFC system, custom design PCBFC, and 500W PCBFC stack. Bramble Energy was founded in 2016 and is based in London, England, United Kingdom.

Carbon Re is a climate technology company developing artificial intelligence to decarbonize energy-intensive industries. It intends to use AI technology to reduce carbon emissions by gigatonnes per year. Its emphasis is on energy-intensive industries like cement, steel, and glass, which account for more than 20% of global emissions. Deep learning is used by Carbon Re's Delta Zero platform for industrial decarbonization to enable rapid development and deployment of new low-carbon industrial processes, designs, and materials.

Apollo Therapeutics is a collaborative venture between three UK universities (Imperial College London, University College London, and the University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, and Johnson & Johnson Innovation). It provides committed translational funding and drug discovery expertise for novel therapeutics, sourced from the best British academic research, accelerating them towards the clinic. Apollo’s unique model provides quick, independent access to the resources to grow innovations and champion the best British academic research to industry. Apollo’s experienced team of industry scientists has a proven track record of therapeutic delivery and works in partnership with academics and industry partners, crafting each bespoke project to optimize the chances of long-term success. Apollo Therapeutics aims to create future therapies by partnering with the UK’s globally leading academic science base and UK-based Pharma industry to have a real impact on patient treatments and outcomes.

Intrinsic Semiconductor Technologies is established to developed silicon-oxide based RRAM technologies. Intrinsic's technology is fully air stable and inherently CMOS compatible. Intrinsic's core technology can be configured as non-volatile memory, multilevel memory, hardware acceleration for Machine Learning, and neuromorphic devices.

Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Nozzle.ai is an eCommerce and advertising optimization platform for Amazon. Nozzle.ai delivers direct-to-consumer level insights about customers on Amazon to beat the competition and grow businesses. Nozzle.ai aims to simplify the selling experience on Amazon.

Bramble Energy is an innovator energy technology company that designs and manufactures high-performance, low-cost, and fuel cell stack. The company ability to leverage the global high-volume PCB industry means that they are the first fuel cell company with the manufacturing capacity to supply gigawatts of fuel cell hardware, something the battery industry has spent many years and £B’s to achieve. Bramble Energy specifically uses a printed circuit board (PCB) technology to form the structural parts of the fuel cell. It also provides products including modular PCBFC stacks, H20:20W PCBFC system, custom design PCBFC, and 500W PCBFC stack. Bramble Energy was founded in 2016 and is based in London, England, United Kingdom.

Teams at Gusto, Vanta and Duolingo use Humanloop to ship reliable AI products. We enable you to adopt best practices for prompt management, evaluation and observability.

AstronauTx aims to restore astrocyte homeostasis function as a treatment for dementias. In a healthy brain, astrocytes support neuronal firing, metabolism, and blood-brain barrier function; however, in disease, they can exacerbate and even drive neurotoxicity.

Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Astroscreen protects brands and defends democracy from harmful social media manipulation campaigns also known as astroturfing.

Phasecraft is a group of world-class quantum scientists and engineers who are tackling grand challenges by expediting the practical application of quantum computing. The company envisions a world in which breakthrough scientific discoveries are commonplace, allowing entrepreneurs to address the world's most pressing concerns more quickly.

Context Scout aims to revolutionise the way every person uses the web. We're building the next generation in web assistance technology - a content-aware browser that doesn’t just show you webpages, but one that reads and comprehends the content, understands what you are trying to do online (making sense of tasks across multiple tabs), and helps you get it done. The world's first web browser chatbot - Your digital assistant for getting anything done online ** Under Development ** Soon we will be able to assist you with: * Online Shopping Scout will find alternative prices, discounts, reviews and summarise your shopping in time for your purchase decision. * Event Planning Scout will check your calendar to see if you're available and plan out your route to the event. * And everything else Need to know how many calories are in the recipe you're looking at? Need the perfect gif for your tweet? Want to find out what people are saying on social m

KIT-AR creates industrial-strength products for a variety of industries, including automotive, aerospace, and electronics. It assists manufacturers in reducing production errors by connecting and improving shopfloor employees. They are now able to get it right the first time, every time, all the time, thanks to their augmented reality (AR) and artificial intelligence (AI) products. The company was founded in 2018 and is based in London, England, United Kingdom.

Data has never been more valuable. But with growing privacy demands and tightening regulations, most of the world’s data is locked away and unusable. For businesses to make better decisions, develop new technologies and deliver more value for customers, they need data they can actually use. They need to set their data free to do more. Hazy is pioneering the new data. We’re the world’s leading synthetic data company, re-engineering enterprise data so that it can be: - Shared without restrictions - data that can move freely, without restriction, to where it’s needed most in businesses and society - Used without limits - data that’s reliable, safe and easy for people and businesses to use to solve problems and create new value. - Trusted without question - data that’s open, transparent and trusted by people, businesses and society.

Freeline is a clinical biotechnology company that develops transformative adeno-associated virus-vector-mediated systemic gene therapies. They use a designed AAV vector and capsid along with novel promoters and transgenes to deliver a functional copy of a therapeutic gene into human liver cells to express a functional level of the missing or dysfunctional protein into the patient’s bloodstream. Their development programs including clinical trials focus on developing products.

Glialign is developing a novel cell therapy for peripheral nerve repair — for which current therapies are only successful in less than half of the cases and often can require grafting of a nerve from another part of the body.

Nozzle.ai is an eCommerce and advertising optimization platform for Amazon. Nozzle.ai delivers direct-to-consumer level insights about customers on Amazon to beat the competition and grow businesses. Nozzle.ai aims to simplify the selling experience on Amazon.

Data has never been more valuable. But with growing privacy demands and tightening regulations, most of the world’s data is locked away and unusable. For businesses to make better decisions, develop new technologies and deliver more value for customers, they need data they can actually use. They need to set their data free to do more. Hazy is pioneering the new data. We’re the world’s leading synthetic data company, re-engineering enterprise data so that it can be: - Shared without restrictions - data that can move freely, without restriction, to where it’s needed most in businesses and society - Used without limits - data that’s reliable, safe and easy for people and businesses to use to solve problems and create new value. - Trusted without question - data that’s open, transparent and trusted by people, businesses and society.

Orchard Therapeutics is a fully integrated commercial-stage company dedicated to treating the lives of patients with rare diseases through innovative gene therapies. Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott-Aldrich syndrome), and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline. The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.

MeiraGTx is committed to the development and commercialization of innovative gene therapy products to transform the lives of patients suffering from acquired and inherited disorders. The company is dedicated to advancing innovative treatments for patients with serious medical conditions. MeiraGTx's research and development efforts primarily revolve around gene therapy, a cutting-edge approach that involves modifying or replacing faulty genes to treat or prevent diseases. Led by an experienced management team, we have taken a portfolio approach by licensing, acquiring, and developing technologies that give us depth across both product candidates and indications. Though initially focusing on the eye, salivary gland, and central nervous system, we intend to expand our focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

Bloomsbury AI offers web services that enables individuals to create, use, and share text-understanding computer applications. The company aims to help their customers to automate their expertise by a written dialog with computers. Bloomsbury AI was launched by Guillaume Bouchard, Tim Rocktäschel, Matko Bosnjak, Sameer Singh, Luis Ulloa, and Sebastian Riedel in April 2015 and is based in London, England.

Freeline is a clinical biotechnology company that develops transformative adeno-associated virus-vector-mediated systemic gene therapies. They use a designed AAV vector and capsid along with novel promoters and transgenes to deliver a functional copy of a therapeutic gene into human liver cells to express a functional level of the missing or dysfunctional protein into the patient’s bloodstream. Their development programs including clinical trials focus on developing products.

Orchard Therapeutics is a fully integrated commercial-stage company dedicated to treating the lives of patients with rare diseases through innovative gene therapies. Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott-Aldrich syndrome), and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline. The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.